Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Our graduate programs go beyond mainstream thought and practices, fostering intellectual inquiry and creative mastery. Master's and doctoral students work with renowned faculty who are scholars, ...

Spend your next few years studying at a center of intensive scholarship and boundless creativity and taking advantage of our multidimensional academic experience. Only here can you study a variety of ...